<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753597</url>
  </required_header>
  <id_info>
    <org_study_id>NUTH/2006/4071</org_study_id>
    <secondary_id>EU ID: 2007-003062-18</secondary_id>
    <nct_id>NCT00753597</nct_id>
  </id_info>
  <brief_title>Rescue of Steroidogenic Capacity in Adrenocortical Failure Study (RADS)</brief_title>
  <acronym>RADS</acronym>
  <official_title>Immunotherapeutic Rescue of Steroidogenic Function in Autoimmune Adrenocortical Failure: Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Newcastle University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Newcastle-upon-Tyne Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Newcastle University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study of B lymphocyte depletion therapy in an attempt to salvage adrenal
      steroidogenic capacity in ten subjects with early autoimmune Addison's disease. During the
      first twelve weeks of treatment, additional glucocorticoid therapy (prednisolone) will be
      given to ensure wellbeing and to rest the steroidogenic apparatus that is the target of the
      autoimmune attack. Glucocorticoids will be gradually withdrawn, in a controlled fashion, and
      adrenal function re-evaluated at 13, 26, 39 and 52 weeks. The primary endpoint will be
      restoration of steroidogenic function as judged by conventional endocrine indices of
      adrenocortical function. B cell depletion may ameliorate the autoimmune attack against
      adrenal cells, potentially allowing a state of immune tolerance to be restored with
      subsequent recovery of adrenal steroidogenic capacity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak serum cortisol, basal or post ACTH</measure>
    <time_frame>13, 26, 39, 52 weeks from first treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>21-OHase antibodies</measure>
    <time_frame>13, 26,39, 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Autoimmune Adrenocortical Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving active treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solu-medrone, Mabthera</intervention_name>
    <description>125mg, 1gram, twice day 1 and day 15</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clear evidence of primary adrenal failure (elevated ACTH, pigmentation, electrolyte
             disturbance)

          -  Basal or stimulated cortisol &lt;400 nmol/l but &gt;100nmol/l

        Exclusion Criteria:

          -  Active viral infection, pregnancy or breast feeding, previous immunosuppression,
             diabetes, cardiorespiratory disease, renal failure, hepatic disease, cancer

          -  Calcified or enlarged adrenals on CT scan, active TB
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Pearce, MD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Newcastle University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Facility, Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2008</study_first_submitted>
  <study_first_submitted_qc>September 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <last_update_submitted>February 5, 2013</last_update_submitted>
  <last_update_submitted_qc>February 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Newcastle University</investigator_affiliation>
    <investigator_full_name>SHS Pearce</investigator_full_name>
    <investigator_title>Professor of Endocrinology</investigator_title>
  </responsible_party>
  <keyword>B cell depletion</keyword>
  <keyword>steroidogenesis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

